

Product Name : palovarotene

**Synonyms** : RO-3300074; RO 3300074; RO3300074; R-667

**Cat No.** : M17504

**CAS Number** : 410528-02-8

Molecular Formula : C27H30N2O2

Formula Weight : 414.55

Chemical Name : 4-((1E)-2-(5,5,8,8-Tetramethyl-3-(1H-pyrazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl)benzoic acid

Palovarotene, also known as RO-3300074 and R-667, is a highly selective retinoic acid receptor gamma (RAR- $\gamma$ ) agonist that is under investigation as a potential treatment for emphysema. Phase I clinical trials of palovarotene in patients with

**Description**emphysema demonstrated that the drug is well tolerated, with improvements observed in markers of emphysema progression. Emphysema is characterized by the destruction of alveoli and alveolar ducts within the lungs. Retinoid

signaling is believed to play a role in alveologenesis, with the retinoic acid receptor gamma thought to be required for

alveolar formation.

Pathway : Angiogenesis

Target : c-Met/HGFR

Receptor : RARy

**Solubility** : DMSO : 19.5 mg/mL. 47.04 mM;

**SMILES** : O=C(O)c1ccc(cc1)/C=C/c3cc4c(cc3Cn2cccn2)C(C)(C)CCC4(C)C

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Pavey GJ, et al. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model. Bone. 2016 Sep;90:159-67.